Harmony Biosciences Holdings, Inc.

Ladies and gentlemen, thank you for standing by, and welcome to the Harmony Bioscientist third quarter 2021 financial update call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask the question during this session, you will need to press star then one on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star then zero. I would now like to turn the conference over to your speaker for today, Patty Beink. You may begin.

Patty Beink Thank you, operator. Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences Third Quarter 2021 Financial Performance and provide a business update. Before we start, I encourage everyone to go to the investor section of the Harmony Biosciences website to find the press release and slides that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our life cycle, we believe non-GAAP financial results better represent the underlying economics of our business. Our presenters on today's call are John Jacobs, President and CEO, Dr. Jeffrey Dano, Chief Medical Officer, Jeffrey Dirks, Chief Commercial Officer, and Sandeep Kapadia, CFO. Moving on to slide two, as a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors reference in our SEC filings for additional details. I would now like to turn the call over to Harmony Biosciences CEO, John Jacobs. John?

Thank you, Patty. And I would also like to extend my sincere thanks to all of the participants for joining our third quarter 2021 conference call today. We are three quarters through the year, and I'm extremely pleased with the progress our team has made to date. Please allow me to elaborate on our achievements in the context of our three pillars growth strategy, which is shown on slide number three. Pillar one is to optimize the commercial performance of WACIX. Q3 represented our seventh quarter of consecutive growth for WACIX and another strong quarter for Harmony as we delivered almost $81 million in net sales, our strongest quarter to date. This significant growth, nearly 77% versus Q3 2020, was driven by a continued increase in the average number of patients on WACIX and in the number of healthcare professionals prescribing the product. We believe this reflects greater awareness of the unique mechanism of action of WACIX and a product profile that aligns well with the existing unmet needs of narcolepsy patients. Moving on to Pillar 2, which is to expand the clinical utility of WACIX beyond narcolepsy, we continue to advance our clinical programs in Prader-Willi Syndrome, or PWS, and myotonic dystrophy, or DM, and two additional rare disease patient populations beyond narcolepsy, both of which have significant unmet medical need and where there are no or limited approved therapies. We are also continuing to evaluate additional indications for pitulicin in other rare neurological diseases. We intend to broaden our lifecycle management efforts for this unique product consistent with our strategy for long-term growth. And finally, pillar three, acquire new assets to expand our portfolio beyond WACICS. Our business development strategy is intended to transform Harmony into a multi-product company with a robust, catalyst-rich pipeline of innovative therapies at various stages of development with a potential for launch both during and after WACIC's lifecycle. We announced in August that we acquired HBS-102, a melanin-concentrating hormone receptor 1 antagonist, which is the first additional asset in our pipeline beyond WACIC's. This is the first example of how we intend to evolve Harmony's pipeline into a portfolio of innovative therapies focused on rare neurological diseases. HBS 102 may be our first acquisition, but our intention is that it won't be our last. An important aspect of this pillar is that we intend to focus on assets where we can leverage our existing expertise and infrastructure, which should enable us to optimize development and launch while managing costs. Importantly, the strategic financing collaboration with Blackstone that we announced last quarter provides us with additional access to capital, which should further enhance our ability to execute on this key pillar for future growth. Finally, our dedicated business development team continues to assess opportunities that are aligned with our strategy, and we look forward to sharing further progress in this area on future calls. On that note, I would like to turn the call over to Jeff Dirks, our Chief Commercial Officer.